Top 23 Companies in Global Antithrombin Market (2025–2035): Competitive Analysis and Forecast Description
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Antithrombin Market Size is projected to Grow from USD 659.8 Million in 2024 to USD 1191 Million by 2035, at a CAGR of 5.52% during the forecast period 2025–2035. The Global antithrombin market is driven by the rising prevalence of blood disorders, increasing surgical procedures, and growing demand for anticoagulant therapies. Advancements in plasma-derived and recombinant products, improved diagnosis, and expanding healthcare infrastructure, along with awareness of thrombosis prevention, are further accelerating market growth worldwide.
Introduction
The global antithrombin market refers to the segment of the pharmaceutical and biotechnology industry that focuses on antithrombin therapies and biologics used to prevent and treat blood clotting disorders, including thrombosis, hereditary antithrombin deficiency, and other coagulation-related conditions. Antithrombin products, typically derived from human plasma or produced via recombinant technologies, regulate blood coagulation, reduce the risk of thromboembolic events, and improve patient safety and outcomes. The market is expanding rapidly due to the rising prevalence of cardiovascular diseases, increasing incidence of venous thromboembolism, and growing demand for effective anticoagulant therapies. Advancements in recombinant antithrombin production, plasma-derived therapies, and novel delivery methods are further driving market growth. Technological developments in biosimilar antithrombin, targeted therapies, and safer formulations are enhancing efficacy, reducing side effects, and improving patient adherence. Increasing hospital-based treatments, prophylactic therapies for high-risk patients, and expanding clinical applications support broader market expansion. Additionally, emerging regions such as the Asia-Pacific are witnessing accelerated adoption due to growing healthcare infrastructure, rising awareness of blood clotting disorders, and increased access to advanced therapeutics. Rising investments in biopharmaceutical manufacturing and supportive government healthcare initiatives further contribute to demand. The global antithrombin market highlights the critical role of these therapies in managing coagulation disorders, improving patient safety, and supporting advancements in cardiovascular and hematology healthcare worldwide.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Antithrombin Market.
Global Antithrombin Market Size, Share, By Product Type (Plasma-Derived Antithrombin, Recombinant Antithrombin), By Application (Therapeutics, Surgical Procedures, Pregnancy Complications, Others), By End-User (Hospitals, Clinics, Research Institutes) and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa) Analysis and Forecast 2024 - 2035
Antithrombin Market Size & Statistics
- The Market Size for the antithrombin market Was Estimated to be worth USD 659.8 million in 2024.
- The Market is Going to Expand at a CAGR of 5.52% between 2025 and 2035.
- The Global antithrombin market Size is anticipated to reach USD 1191 million by 2035.
- North America is expected to generate the highest demand during the forecast period in the antithrombin market
- Asia‑Pacific is expected to grow the fastest during the forecast period in the antithrombin market.
Regional growth and demand
Asia‑Pacific is expected to grow the fastest during the forecast period in the antithrombin market. Asia‑Pacific is expected to grow fastest due to rising prevalence of cardiovascular and thromboembolic disorders, expanding healthcare infrastructure, and increasing access to advanced therapies in countries like China, India, and Japan. Growing awareness of coagulation disorders and higher investments in biopharmaceutical manufacturing further drive market adoption in the region.
North America is expected to generate the highest demand during the forecast period in the antithrombin market. North America is expected to generate the highest demand due to its large aging population, high healthcare expenditure, and strong adoption of advanced technologies like AI and IoT. Well-established healthcare infrastructure, supportive government policies, and the presence of leading market players further drive widespread adoption of ambient assisted living solutions across the region.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Antithrombin Market.
Ready to lead the Antithrombin Market?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Antithrombin Market
- Rising prevalence of thrombotic disorders
- Shift toward recombinant antithrombin products
- Growth in surgical and critical care applications
- Increasing R&D and clinical innovation
- Expansion of diagnostic applications
- Adoption of personalized medicine approaches
- Development of long-acting extended half-life therapies
- Use of transgenic animal technology for production
- Expansion in emerging markets Asia-Pacific growth
- Integration of advanced diagnostics and AI in coagulation testing
1. Rising prevalence of thrombotic disorders
The global increase in thrombotic conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE) is a major driver of antithrombin demand. Contributing factors include aging populations, sedentary lifestyles, cancer, and surgical procedures. This escalating disease burden is prompting greater use of antithrombin therapies to prevent or manage blood clot formation, particularly in hospital and critical care settings.
2. Shift toward recombinant antithrombin products
There is a clear trend from traditional plasma‑derived antithrombin toward recombinant formulations produced using biotechnology (for example, transgenic animals like goats). These products offer advantages in safety (reduced risk of blood‑borne infections), consistency, and availability. Recombinant antithrombin is increasingly favored in surgical prophylaxis and high‑risk clinical applications, and a significant portion of new R&D efforts is focused on these biotech‑derived options.
3. Growth in surgical and critical care applications
Antithrombin is used extensively in settings such as cardiac surgery, organ transplantation, extracorporeal membrane oxygenation (ECMO), and other high‑risk procedures to manage coagulation and reduce thrombosis risk. With rising volumes of complex surgical procedures globally, demand for antithrombin therapies in these clinical care areas continues to expand, sustaining a strong market segment for therapeutic products.
4. Increasing R&D and clinical innovation
Industry players are investing heavily in research to broaden antithrombin’s medical applications and to improve product characteristics such as safety, bioavailability, and dosing convenience. Reports indicate many active projects targeting novel indications beyond hereditary deficiencies (such as sepsis, inflammatory conditions), as well as advanced delivery systems and extended half‑life formulations. This R&D focus supports ongoing clinical innovation and future market growth.
5. Expansion of diagnostic applications
Alongside therapeutic use, the diagnostics segment is gaining importance. Accurate measurement of antithrombin levels is essential for early detection and management of coagulation disorders. Advances in diagnostic assays and technologies including assays incorporated into automated lab equipment are driving higher adoption of antithrombin testing in clinical labs, supporting broader disease screening and personalized therapy decisions.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the antithrombin market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Antithrombin Market.
Top 25 Companies Leading the Antithrombin market
- CSL Behring.
- Grifols SA
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- LFB USA
- Kedrion SpA
- Lee Biosolutions
- Scripps Laboratories
- rEVO Biologics Inc
- Thermo Fisher Scientific
- Siemens Healthcare GmbH
- Diapharma Group Inc
- Merck KGaA
- Pfizer Inc
- Sanofi
- Novartis AG
- Bio Techne Corporation
- Biocon Ltd
- Jiangsu Hengrui Medicine Co Ltd
- China Biologic Products Inc
- Baxter International Inc
- Bio Products Laboratory Ltd
- LEO Pharma AS
- Sysmex Corporation
- Koliber Biosciences.
- CSL Behring
Headquarters: King of Prussia, Pennsylvania, USA
CSL Behring is a global leader in plasma-derived and recombinant therapies, including antithrombin concentrates. The company focuses on hereditary antithrombin deficiency treatment, surgical prophylaxis, and critical care applications. Its investment in R&D, plasma fractionation technology, and global distribution networks makes it a major driver of antithrombin market growth worldwide.
2. Grifols SA
Headquarters: Barcelona, Spain
Grifols specializes in plasma-derived protein therapeutics and is a key supplier of antithrombin products for hospitals and surgical centers. The company emphasizes quality plasma collection, safety, and consistency in production. Its strong European presence and expanding global operations support continued market expansion in antithrombin therapies.
3. Takeda Pharmaceutical Company Limited
Headquarters: Tokyo, Japan
Takeda is a leading global pharmaceutical company with a strong portfolio in hematology and plasma-derived therapies, including antithrombin. The company emphasizes innovation, strategic acquisitions, and global distribution. Its R&D focus and robust supply chains enable wider access to antithrombin products, driving growth in critical care and surgical markets.
4. Octapharma AG
Headquarters: Lachen, Switzerland
Octapharma produces high-purity plasma-derived and recombinant antithrombin therapies. The company emphasizes product safety, efficacy, and compliance with international standards. Its global operations, particularly in Europe and North America, and commitment to research in coagulation disorders make it a significant contributor to antithrombin market growth.
5. LFB USA
Headquarters: Les Ulis, France (U.S. Operations)
LFB USA specializes in plasma proteins and biotherapies, including antithrombin. The company focuses on niche markets in surgical and critical care settings, emphasizing quality, reliability, and patient safety. Its presence in North America and strategic collaborations enable targeted growth in antithrombin therapies.
Are you ready to discover more about the Antithrombin market?
The report provides an in-depth analysis of the leading companies operating in the global antithrombin market. It includes a comparative assessment based on their product portfolios, businesss overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Antithrombin Market.
Company Profiles
- CSL Behring.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Grifols SA
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- LFB USA
- Kedrion SpA
- Lee Biosolutions
- Scripps Laboratories
- rEVO Biologics Inc
- Others
Our Reports
https://www.sphericalinsights.com/reports/europe-anti-aging-supplements-market
https://www.sphericalinsights.com/reports/europe-ophthalmic-drugs-market
https://www.sphericalinsights.com/reports/europe-methanol-market
https://www.sphericalinsights.com/reports/germany-asphalt-pavers-market
https://www.sphericalinsights.com/reports/france-fertility-services-market
Conclusion
The global antithrombin market is witnessing steady growth, driven by rising demand in the management of thrombotic disorders, hereditary antithrombin deficiency, surgical procedures requiring anticoagulation, and chronic cardiovascular conditions. Advanced technologies such as recombinant antithrombin production, improved plasma-derived formulations, genetic screening, and advanced diagnostic assays provide accurate monitoring, predictive analytics, and enhanced therapeutic outcomes, enabling safer, more effective, and patient-optimized treatment environments. Innovations such as recombinant biologics, AI-driven predictive care models, cloud-based clinical data platforms, and automated patient monitoring systems further improve service quality, operational efficiency, and patient experience. Leading companies such as Grifols S.A., Takeda Pharmaceutical Company Limited, Kedrion Biopharma, Bio Products Laboratory Ltd., and CSL Behring are expanding their global presence, offering technologically advanced, high-performance, and patient-friendly antithrombin therapies. Overall, antithrombin products and technologies are playing a vital role in healthcare, hospital care, chronic disease management, and surgical settings, while driving innovation, scalability, and sustainable, patient-centric solutions worldwide.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?